This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Osteoblast, Adipocytes, Bone Density, Osteocalcin, Adiponectin or Mesenchymal Stem Cells
and you are
between 18 and 80
years old
-
The phase for this study is not defined.
Show me locations

The purpose

We will prospectively study 2 groups of diabetic patients treated with pioglitazone or placebo for 26 weeks. Bone marrow aspirates will be obtained from these patients at baseline and after 26 weeks of treatment, and hBMCs will be isolated from these bone marrow aspirations. The ability of hBMCs to differentiate into osteoblast and adipocytes lineages will be compared before and after treatment with pioglitazone and compared to placebo. In parallel, clinical markers of bone formation and resorption as well as bone mineral density will be assessed before and after 26 weeks of treatment. Primary endpoint for this study will be detection of change in number of osteoblasts or adipocytes from cultured hBMCs between study groups and within each group.

Provided treatments

  • Drug: Pioglitazone
  • Drug: Placebo
Tris trial is registered with FDA with number: NCT00927355. The sponsor of the trial is Emory University and it is looking for 10 volunteers for the current phase.
Official trial title:
Effects of Thiazolidinediones on Human Bone Marrow Stromal Cell Differentiation Capacity:In Vitro and In Vivo- A Pilot Study